Shire: Clinical Trials

134 completed, 23 terminated, 7 withdrawn, 2 active not recruiting. 167 Phase 3, 7 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	167	Completed 134, Terminated 23, Withdrawn 7, Active not recruiting 2, Unknown 1
Phase 2	7	Completed 6, Withdrawn 1

Follow Shire: new trials by email

Trials (filtered) newest first · largest first

All 167 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism rhPTH(1-84) - Chronic Hypoparathyroidism	Phase 3	Withdrawn	Shire		2022-08-31	2022-10-10
Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications Teduglutide, Placebo - Ileostomy - Stoma	Phase 3	Withdrawn	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)		2022-06-02	2023-02-23
A Study of Replagal in Treatment-naïve Adults With Fabry Disease REPLAGAL - Fabry Disease	Phase 3	Terminated	Shire	17	2021-12-28	2024-06-17
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura TAK-755 - Thrombotic Thrombocytopenic Purpura (TTP)	Phase 3	Active not recruiting	Takeda	77	2021-04-14	2026-04-02
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Lanadelumab - Angioedema	Phase 3	Completed	Shire	73	2021-02-05	2024-06-17
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE) Lanadelumab - Hereditary Angioedema (HAE)	Phase 3	Completed	Shire	12	2019-12-12	2022-09-30
A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children Lanadelumab - Hereditary Angioedema	Phase 3	Completed	Shire	21	2019-08-19	2022-05-26
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) Ontamalimab, Placebo - Crohn's Disease	Phase 3	Terminated	Shire	40	2019-02-06	2022-03-31
Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism rhPTH(1-84) - Hypoparathyroidism	Phase 3	Terminated	Shire	22	2018-09-26	2022-10-07
Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Teduglutide, Standard Medical Therapy, Syringe - Short Bowel Syndrome	Phase 3	Completed	Shire	10	2018-08-31	2021-05-11
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) Ontamalimab, Placebo - Crohn's Disease	Phase 3	Terminated	Shire	30	2018-08-29	2021-04-29
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) Ontamalimab, Placebo - Crohn's Disease	Phase 3	Terminated	Shire	34	2018-07-17	2021-05-11
Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Teduglutide, Syringe, Needle - Short Bowel Syndrome	Phase 3	Completed	Shire	7	2018-07-06	2020-08-04
Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting SHP615, MHOS/SHP615 - Nervous System Diseases	Phase 3	Completed	Shire	3	2018-04-23	2021-09-14
An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis Ontamalimab, Placebo - Ulcerative Colitis	Phase 3	Completed	Shire	366	2018-04-04	2022-01-14
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) 25 mg Ontamalimab, 75 mg Ontamalimab - Crohn's Disease, Ulcerative Colitis	Phase 3	Completed	Shire	557	2018-02-27	2024-06-21
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis Ontamalimab, Placebo - Ulcerative Colitis	Phase 3	Terminated	Shire	380	2018-02-09	2021-06-14
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) SHP465 - Attention Deficit Hyperactivity Disorder (ADHD)	Phase 3	Terminated	Shire	141	2018-01-02	2021-06-03
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years SHP465, Placebo - Attention Deficit Hyperactivity Disorder (ADHD)	Phase 3	Completed	Shire	89	2017-12-09	2021-06-02
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis Ontamalimab, Placebo - Ulcerative Colitis	Phase 3	Terminated	Shire	279	2017-12-05	2021-04-26

Showing 20 of 167. Sign in to see all of them.

Conditions studied

Attention Deficit Disorder with Hyperactivity (35)  ·  Angioedemas, Hereditary (21)  ·  Short Bowel Syndrome (14)  ·  Colitis, Ulcerative (9)  ·  Gaucher Disease (6)  ·  Hyperphagia (6)  ·  Hypoparathyroidism (6)  ·  Binge-Eating Disorder (5)  ·  Crohn Disease (4)  ·  Dry Eye Syndromes (4)  ·  Fabry Disease (4)  ·  Kidney Failure, Chronic (4)  ·  Mucopolysaccharidosis II (4)  ·  Osteoporosis (4)  ·  Depressive Disorder, Major (3)

Interventions

Lisdexamfetamine Dimesylate (26)  ·  teduglutide (14)  ·  Guanfacine (8)  ·  lanthanum carbonate (8)  ·  icatibant (7)  ·  ontamalimab (7)  ·  ALX-0600 (6)  ·  Glucosylceramidase (6)  ·  Mesalamine (6)  ·  Complement C1 Inhibitor Protein (5)  ·  lanadelumab (5)  ·  agalsidase alfa (4)  ·  ecallantide (4)  ·  lifitegrast (4)  ·  maribavir (4)

Countries

United States (116)  ·  United Kingdom (46)  ·  Canada (45)  ·  Germany (44)  ·  Spain (39)  ·  Italy (32)  ·  Poland (30)  ·  France (28)  ·  Japan (26)  ·  Belgium (25)  ·  Hungary (24)  ·  Israel (23)  ·  Australia (18)  ·  Netherlands (18)  ·  Romania (18)

Top investigators

Andries Korebrits, prof. Dr. (1)  ·  Anna G Nilsson, MD, PhD (1)  ·  Barbara Finck, MD (1)  ·  Barbara K Finck, M.D. (1)  ·  Chris J Gordon, FRCP (1)  ·  Claire Spice, MRCP (1)  ·  Csaba P. Kovesdy, M.D. (1)  ·  Edmund Sonuga-Barke, PhD (1)  ·  Frederick W. Reimherr, MD (1)  ·  Herbert Roeyers, PhD (1)  ·  James McCormick, DO (1)

Results publications

PMID 36326435, PMID 20818886, PMID 23312695, PMID 36018496, PMID 38096402, PMID 23548529, PMID 23878046, PMID 24712435, PMID 27839979, PMID 32237290, PMID 32738041, PMID 35696069, PMID 35974422, PMID 37364133, PMID 40576086, PMID 20818888, PMID 20861587, PMID 21130380, PMID 21317170, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 24134154, PMID 25038431, PMID 26346638, PMID 27474961, PMID 27507402, PMID 29497297, PMID 30013816, PMID 30817099, PMID 34182150, PMID 35961250, PMID 36153561, PMID 37028510, PMID 37889619, PMID 37915038, PMID 38873891, PMID 39735351, PMID 41858082, PMID 16099790, PMID 16678648, PMID 17073887, PMID 17234558, PMID 17241860, PMID 17339618, PMID 17577466, PMID 17999759, PMID 18166547, PMID 18272546

NIH funding

2004 (8), 2009 (7), 2017 (7), 2008 (6), 2015 (5), 2016 (5), 2014 (2), 2018 (2), 2019 (1)